MSAID

What MSAID does

MSAID GmbH is a German artificial-intelligence software company that develops deep-learning tools for mass-spectrometry-based proteomics. Founded in 2019 as a spin-off from the Chair of Proteomics and Bioanalytics at the Technical University of Munich, the company is headquartered in Garching bei München and serves pharmaceutical, biotechnology, academic, and government research laboratories worldwide. Its leadership team combines proteomics scientists and machine learning engineers, including Dr. Martin Frejno (CEO), Dr. Daniel Zolg (COO), and Prof. Dr. Mathias Wilhelm and Prof. Dr. Bernhard Kuster as scientific advisors.

The company's core products are CHIMERYS, an AI-powered spectrum-centric search algorithm that deconvolutes chimeric MS2 spectra in tandem mass spectrometry and supports DDA, DIA, and PRM acquisition methods; INFERYS Rescoring, a deep-learning module that rescores peptide-spectrum matches from classical search engines such as Sequest HT using intensity-based metrics; and the MSAID Platform, a cloud-native service for proteomics data ingestion, processing, storage, and browser-based analysis with API integration. The underlying technology stack combines proprietary deep-learning frameworks trained on millions of mass spectra with C++-optimized compute running on AWS infrastructure powered by more than 65% renewable energy. Products are delivered through the cloud platform, as embedded modules in Thermo Scientific Proteome Discoverer software, and via on-premise server deployments for HPC environments.

MSAID generates revenue through software subscription licenses (cloud platform and enterprise on-premise), professional services including custom deep-learning model development and in-silico spectral library generation, and consulting engagements. The primary distribution channel is the Thermo Scientific Proteome Discoverer OEM integration, complemented by direct enterprise sales, on-premise deployments, and academic licensing. In June 2026, Thermo Fisher Scientific announced the acquisition of MSAID as part of its broader strategy to expand AI-enabled workflows and data intelligence offerings for pharmaceutical and biotechnology customers.

Name

MSAID

Legal name

MSAID GmbH

Website

https://msaid.de

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

MSAID GmbH is a German AI software company that develops deep-learning algorithms, including CHIMERYS and INFERYS, for mass-spectrometry-based proteomics data analysis. It serves pharmaceutical, biotechnology, and academic research laboratories, and was acquired by Thermo Fisher Scientific in 2026.

Ownership category

akta.pro rank

Product category

Proteomics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Proteomics data analysis
• Mass spectrometry software
• Deep learning proteomics
• Peptide identification algorithms
• AI bioinformatics software

Headquarters

HQ city

Garching Bei München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Subscription Licenses (Cloud): MSAID Platform operates on a subscription basis with flexible subscriptions, accessible via API. Users subscribe to the cloud service for proteomics data processing, storage, and analysis.
2. Enterprise Software Licensing (On-Premise): CHIMERYS and INFERYS are integrated into Thermo Scientific Proteome Discoverer software as enterprise-grade licenses, sold as part of Thermo Fisher Scientific's software ecosystem. Also available as on-premise server solution for single servers and HPC environments.
3. Professional Services & Consulting: Custom deep learning model development, deep learning-based data analysis services, custom in-silico spectral library generation, and consulting for proteomics data workflows.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

MSAID develops and sells AI-powered software for mass spectrometry-based proteomics data analysis. Its core offerings are CHIMERYS (a spectrum-centric deep learning search algorithm that deconvolutes chimeric MS2 spectra), INFERYS Rescoring (a deep learning engine that rescores results from classical search engines like Sequest HT), and the MSAID Platform (a cloud-native platform for proteomics data storage, processing, and browser-based analysis). The company also offers professional services including custom deep learning model development, data analysis, spectral library generation, and consulting for proteomics workflows in pharmaceutical, biotechnology, and academic research settings.

Product overview

MSAID offers a platform-plus-modules architecture centered on three core software products: CHIMERYS (AI-powered spectrum-centric search algorithm for bottom-up proteomics), INFERYS Rescoring (deep learning enhancement for classical search engines), and the cloud-based MSAID Platform for scalable proteomics data processing and analysis. These products are complemented by professional services including custom deep learning model development, data analysis services, and spectral library generation. All products are designed for proteomics researchers and leverage deep learning to improve peptide identification accuracy compared to classical algorithms.

Differentiator

Problem solved

Functional benefit

Products and services

• CHIMERYS AI-powered intelligent search algorithm for bottom-up proteomics that deconvolutes chimeric MS2 spectra in tandem mass spectrometry. Supports DDA, DIA, and PRM data acquisition methods with spectrum-centric analysis, capable of identifying up to 2x more peptides than classical search engines. Sold to proteomics researchers in pharma, biotech, and academia via Thermo Scientific Proteome Discoverer integration and on-premise server deployment.
• INFERYS Rescoring Standalone deep learning-based rescoring engine that enhances classical search engines such as Sequest HT by rescoring candidate peptide-spectrum matches using intensity-based metrics for more accurate spectral matches and deeper confidence. Delivers up to 3x more peptide-spectrum-matches than classical workflows. Targeted at proteomics researchers using Thermo Scientific Proteome Discoverer.
• MSAID Platform Scalable cloud platform for proteomics data storage, processing, and browser-based result analysis powered by CHIMERYS 5. Enables raw data ingestion to actionable insights through API integration and flexible subscriptions. Targets enterprise and academic proteomics researchers globally who prefer cloud-based data processing and storage.
• Custom Deep Learning Models Professional service that uses MSAID's generic deep learning framework to expand prediction capabilities and customize them to a client's specific needs, instruments, and infrastructure. Targeted at pharma, biotech, and academic clients requiring bespoke proteomics AI models.
• Deep Learning-Based Data Analysis Service that applies MSAID's advanced AI algorithms to client proteomics data, reliably identifying up to three times more peptide-spectrum-matches than classical workflows. Targeted at pharma, biotech, and academic clients needing outsourced proteomics analysis.
• Custom In-Silico Spectral Libraries Service that generates predicted spectral libraries for any peptide sequence and organism, eliminating the cumbersome and expensive traditional spectral library creation process. Targeted at proteomics researchers requiring comprehensive spectral libraries without experimental generation.
• Consulting Services Expert consulting that leverages MSAID's long-standing expertise in proteomics and proteomic data analysis to help clients test, evaluate, and improve their proteomics data workflows. Targeted at pharma, biotech, and academic clients.

Quantifiable outcome

• Up to 2x more peptide identifications compared to classical search engines (e.g., SequestHT)
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship / core, core and minor.

• Thermo Fisher Scientificflagship / coreStrategic or Co-development Partner · 22 June 2026MSAID was acquired by Thermo Fisher Scientific in June 2026 as part of a broader AI-enabled workflows and data intelligence strategy. MSAID's CHIMERYS and INFERYS products are integrated into Thermo Fisher's software ecosystem (Thermo Scientific Proteome Discoverer). This is a flagship partnership providing global enterprise distribution for MSAID's products. The acquisition was announced alongside other strategic acquisitions including HealthVerity, Datavant, Proteinaceous, and relationships with NVIDIA and OpenAI.
• Technical University of Munich (TUM)coreStrategic or Co-development PartnerMSAID is an informatics spin-off from the Chair of Proteomics and Bioanalytics at Technical University of Munich. Founding team members (including CEO Dr. Martin Frejno, COO Dr. Daniel Zolg, Prof. Dr. Mathias Wilhelm, Prof. Dr. Bernhard Kuster) originate from TUM. The company maintains academic partnerships and scientific advisory relationships with TUM faculty.
• NVIDIAcoreTechnology or IntegrationMSAID is a member of the NVIDIA Inception Program, which supports cutting-edge AI startups. The company's deep learning models for peptide property prediction and spectrum analysis leverage NVIDIA GPU infrastructure. CHIMERYS is developed using NVIDIA technology for compute-intensive deep learning training and inference.
• BSFZ (Bayern Innovativ / Bayerische Forschungsstiftung)minorOthersBSFZ (Bayerische Forschungsstiftung / Bayern Innovativ) is listed as a partner on MSAID's website, indicating some form of support or collaboration with the Bavarian innovation agency. Details of the partnership scope are not disclosed.
• Thermo Scientific (within Thermo Fisher Scientific)flagship / coreOEM/ Whitelabel/ Licensing PartnerCHIMERYS and INFERYS are integrated as embedded search algorithms within Thermo Scientific Proteome Discoverer software. This OEM-style integration allows MSAID to reach all Thermo Scientific mass spectrometry customers globally through Proteome Discoverer's distribution network.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Biognosys: Swiss proteomics software and services company whose SpectroNaut and SpectroDive platforms directly compete with CHIMERYS and INFERYS for DDA/DIA proteomics workflows across pharma and academic labs.
• Protein Metrics (Dotmatics): Develops protein characterization and proteomics informatics software (Byos, PMI-Byos) used in biopharma and academic workflows; now part of Dotmatics, it competes head-to-head with MSAID in biopharma proteomics analysis.
• Schrödinger: Computational chemistry and biology software platform (LiveDesign, Maestro, PyMOL) serving pharma/biotech R&D; comparable as a physics/ML-driven scientific software vendor monetizing advanced algorithms at enterprise scale.

Broad incumbents

• Dotmatics: End-to-end scientific R&D informatics platform (including Protein Metrics and OMIQ) used across pharma discovery; a broad incumbent offering overlapping proteomics capabilities as part of a wider lab-data portfolio.
• Bruker: Major mass spectrometry and proteomics instrument vendor (timsTOF) with its own informatics (e.g., ProteoScape); a broad incumbent whose instrument-plus-software stack competes with Thermo Fisher + MSAID at the workflow level.
• SCIEX: Mass spectrometry instruments and software (e.g., OneOmics, Molecule Profiler) for proteomics and metabolomics; a broad incumbent whose integrated stack overlaps with MSAID's analytical workflows in pharma/biotech.
• Recursion Pharmaceuticals: AI-enabled drug discovery platform combining high-throughput biology with deep learning; comparable as a broad AI-bio incumbent pursuing pharma partnerships and platform-style commercialization.

Emerging players

• BenchSci: AI-powered reagent and experiment-intelligence platform for life-science R&D; comparable as an AI-native vendor embedding ML into wet-lab and analytical workflows for pharma/biotech buyers.
• TetraScience: R&D data cloud and AI platform for scientific data in life sciences; comparable as an enabling data-infrastructure layer that sits alongside instruments and analysis software like MSAID's platform.
• Insilico Medicine: AI-driven drug discovery company using deep learning across biology and chemistry; comparable as a peer applying deep learning to wet-lab biology workflows and competing for pharma AI R&D budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/msaid_de
• YouTubeyoutube.com/@msaid_de
• LinkedInlinkedin.com/company/msaid

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSAID